Multivariate analysis of factors associated with engraftment in patients undergoing myeloablative unrelated donor PBSC transplantation
| Variable . | n . | Engrafted, n . | OR (95% CI) . | P . |
|---|---|---|---|---|
| Day 25 neutrophil engraftment | ||||
| Karnofsky score | .002 | |||
| 90-100 | 364 | 344 | 1.00 | |
| 10-80 | 176 | 151 | 0.37 (0.18-0.64) | < .001 |
| Missing | 56 | 53 | 1.24 (0.34-4.49) | .738 |
| CD34+ cells dose, ×106/kg | .001 | |||
| 3.8 or less | 107 | 94 | 1.00 | |
| More than 3.8 | 319 | 305 | 3.70 (1.61-8.47) | .002 |
| Missing | 170 | 149 | 0.97 (0.45-2.11) | .941 |
| Recipient BMI, kg/m2 | .034 | |||
| Less than 18.5 | 47 | 41 | 0.8 (0.32-2.41) | .798 |
| 18.5-24.9 | 220 | 196 | 1.00 | |
| 25-29.9 | 185 | 175 | 2.36 (1.07-5.22) | .033 |
| 30 or greater | 144 | 136 | 2.72 (1.14-6.46) | .024 |
| Use of planned growth factors | ||||
| No | 412 | 373 | 1.00 | |
| Yes | 184 | 175 | 2.37 (1.08-5.17) | .031 |
| Day 60 platelet 50000 engraftment | ||||
| Karnofsky score | .007 | |||
| 90-100 | 362 | 272 | 1.00 | |
| 10-80 | 180 | 110 | 0.54 (0.36-0.81) | .003 |
| Missing | 52 | 35 | 0.61 (0.32-1.17) | .135 |
| CD34+ cell dose, ×106/kg | < .001 | |||
| 3.8 or less | 102 | 55 | 1.00 | |
| More than 3.8 | 321 | 238 | 2.69 (1.68-4.33) | < .001 |
| Missing | 171 | 125 | 2.48 (1.46-4.21) | < .001 |
| HLA matching status | .016 | |||
| Well-matched | 352 | 261 | 1.00 | |
| Partially matched | 166 | 111 | 0.74 (0.48-1.12) | .150 |
| Mismatched | 76 | 45 | 0.47 (0.27-0.80) | .005 |
| Recipient CMV status | ||||
| Negative | 268 | 202 | 1.00 | |
| Positive | 326 | 215 | 0.68 (0.47-0.99) | .042 |
| Variable . | n . | Engrafted, n . | OR (95% CI) . | P . |
|---|---|---|---|---|
| Day 25 neutrophil engraftment | ||||
| Karnofsky score | .002 | |||
| 90-100 | 364 | 344 | 1.00 | |
| 10-80 | 176 | 151 | 0.37 (0.18-0.64) | < .001 |
| Missing | 56 | 53 | 1.24 (0.34-4.49) | .738 |
| CD34+ cells dose, ×106/kg | .001 | |||
| 3.8 or less | 107 | 94 | 1.00 | |
| More than 3.8 | 319 | 305 | 3.70 (1.61-8.47) | .002 |
| Missing | 170 | 149 | 0.97 (0.45-2.11) | .941 |
| Recipient BMI, kg/m2 | .034 | |||
| Less than 18.5 | 47 | 41 | 0.8 (0.32-2.41) | .798 |
| 18.5-24.9 | 220 | 196 | 1.00 | |
| 25-29.9 | 185 | 175 | 2.36 (1.07-5.22) | .033 |
| 30 or greater | 144 | 136 | 2.72 (1.14-6.46) | .024 |
| Use of planned growth factors | ||||
| No | 412 | 373 | 1.00 | |
| Yes | 184 | 175 | 2.37 (1.08-5.17) | .031 |
| Day 60 platelet 50000 engraftment | ||||
| Karnofsky score | .007 | |||
| 90-100 | 362 | 272 | 1.00 | |
| 10-80 | 180 | 110 | 0.54 (0.36-0.81) | .003 |
| Missing | 52 | 35 | 0.61 (0.32-1.17) | .135 |
| CD34+ cell dose, ×106/kg | < .001 | |||
| 3.8 or less | 102 | 55 | 1.00 | |
| More than 3.8 | 321 | 238 | 2.69 (1.68-4.33) | < .001 |
| Missing | 171 | 125 | 2.48 (1.46-4.21) | < .001 |
| HLA matching status | .016 | |||
| Well-matched | 352 | 261 | 1.00 | |
| Partially matched | 166 | 111 | 0.74 (0.48-1.12) | .150 |
| Mismatched | 76 | 45 | 0.47 (0.27-0.80) | .005 |
| Recipient CMV status | ||||
| Negative | 268 | 202 | 1.00 | |
| Positive | 326 | 215 | 0.68 (0.47-0.99) | .042 |